Natural products represent the traditional source of new drug candidates [1]. A global overview on the metabolic wealth of fungal secondary metabolites ± prominent and less prominent ones ± is provided in diverse compilations [2], [3]. From the systematic viewpoint, the most prolific producers of pharmaceutically relevant molecules are the ascomycetes. Their evolutionary counterpart, the basidiomycetes, are equally rich and often unique in their secondary metabolism, however, they cannot compare for significance in terms of clinically used compounds. We open our review with spotlights in the history of pharmacy to underline the Janus-faced nature of fungal metabolites.The Eleusinian Mysteries, initiation ceremonies in the ancient Greek culture that have been established about 1500 BC, climaxed when the initiates reached a visionary state. Their revelatory state of mind was mediated by a drink called ªkykeonº. Today's research attributes this preparation to rye, parasitised by the ergot fungus Claviceps ± a classic in the history of pharmacy. Ergot fungi are known to produce hallucinogenic lysergic acid amides [4]. In the medieval Europe, the sclerotia of the same fungus posed a severe threat to human health when continued ingestion of contaminated bread caused horrible symptoms, like gangrene of the extremities. The order of St. Anthony, in particular, cared for those who were ailing from these symptoms colloquially referred to as ªholy fireº or ªSt. Anthony's fireº. Created in 1515 for an Antonitarian monastery, one painting of the Isenheim Altar symbolises the suffering and the pain of those affected by the toxic metabolites of the ergot fungus. The Isenheim Altar is one of the most outstanding pieces of art ever and marked the onset of the Renaissance. Starting in the 18 th centuryClaviceps sclerotia were pharmaceutically used to induce contractions of the uterus. In the 1930 s, the ergot alkaloids served as a molecular template for the synthesis of the lysergic acid diethylamide (LSD) by Albert Hofmann and co-workers at the San-
AbstractFilamentous fungi produce a plethora of bioactive natural products. These metabolites display a broad range of useful activities for pharmaceutical purposes, exemplified best by the antibiotic penicillin. Yet, many more have been isolated, characterised, and tested, and some have made their way in clinical trials and into pharmaceutical practice. Through genomics, we become increasingly aware that the biosynthetic abilities for natural products are much richer than expected. The first part of our review highlights selected metabolites that filamentous fungi offer to pharmacists for drug development. This is followed by a summary on the potential of fungal genetics and genomics for pharmaceutical sciences and natural product research.